Biotangents, a Scottish biotechnology company, secured £2.2m in funding.
The funding was made up from £1.6m from the UK Government’s Innovate UK innovation loans program and a further £600k from a funding round lead by the investment syndicate Kelvin Capital and with Scottish Enterprise participation.
The company intends to use the funds for the development and roll-out of its ‘on farm’ rapid disease detection technology. Biotangents also secured £1.2m in August 2021 in a funding round also led by Kelvin Capital, following an initial £1.5m in May 2019.
Founded in 2015 by Dr Andy Hall-Ponselè and Lina Gasiūnaitė and led by Ian Hamilton, Chairman, Fiona Marshall, CEO, and Ross McDermid, Director of Commercialisation, Biotangents has developed Isothermal technology, which can be applied to the rapid detection of a wide range of diseases in Animal Health including Bovine Viral Diarrhoea (BVD) and Mastitis. The AmpliSpec™ Mastitis diagnostic test will cut the detection time for Mastitis from the current period of several days to just a few hours.
Biotangents is based at the Pentlands Science Park just outside Edinburgh.
FinSMEs
20/05/2022